Study Summary
This trial will help determine if baricitinib is an effective treatment for severe or very severe alopecia areata, and what the best dosage is.
- Alopecia Areata
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
1 Primary · 11 Secondary · Reporting Duration: Week 36
Trial Safety
Phase-Based Safety
Side Effects for
Awards & Highlights
Trial Design
4 Treatment Groups
Open-Label Addenda Baricitinib High Dose
1 of 4
Baricitinib Low Dose
1 of 4
Baricitinib High Dose
1 of 4
Placebo
1 of 4
Experimental Treatment
Non-Treatment Group
824 Total Participants · 4 Treatment Groups
Primary Treatment: Baricitinib · Has Placebo Group · Phase 2 & 3
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18 - 70 · All Participants · 1 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Who else is applying?
What state do they live in?
Texas | 50.0% |
Pennsylvania | 12.5% |
Massachusetts | 12.5% |
Other | 25.0% |
How old are they?
18 - 65 | 100.0% |
What site did they apply to?
Medaphase Inc | 20.0% |
ActivMed Practices and Research | 20.0% |
Penn State Univ. Milton S. Hershey Medical Center | 20.0% |
Other | 40.0% |
What portion of applicants met pre-screening criteria?
Met criteria | 62.5% |
Did not meet criteria | 37.5% |
- King, Brett, Manabu Ohyama, Ohsang Kwon, Abraham Zlotogorski, Justin Ko, Natasha A. Mesinkovska, Maria Hordinsky, et al.. 2022. “Two Phase 3 Trials of Baricitinib for Alopecia Areata”. New England Journal of Medicine. Massachusetts Medical Society. doi:10.1056/nejmoa2110343.
- King, Brett, Manabu Ohyama, Ohsang Kwon, Abraham Zlotogorski, Justin Ko, Natasha A. Mesinkovska, Maria Hordinsky, et al.. 2022. “Two Phase 3 Trials of Baricitinib for Alopecia Areata”. New England Journal of Medicine. Massachusetts Medical Society. doi:10.1056/nejmoa2110343.
- 2018. "A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03570749.
Frequently Asked Questions
For what illnesses is Baricitinib commonly prescribed?
"Baricitinib has shown efficacy in treating patients that are hospitalized with coronavirus disease 2019 (covid‑19) and require extracorporeal membrane oxygenation." - Anonymous Online Contributor
Are there any vacancies in this clinical trial for participants?
"This trial is no longer recruiting participants. It was originally posted on September 24th, 2018 and last updated February 2nd, 2022. However, there are 93 other trials for alopecia areata and 34 for Baricitinib that are still looking for patients to enroll." - Anonymous Online Contributor
What insights have been gleaned from prior research on Baricitinib?
"University of Nebraska Medical Center first researched baricitinib in 2007 and, since then, 18310 similar studies have been completed. As of now, there are 34 ongoing clinical trials with a large portion taking place in New Haven, Connecticut." - Anonymous Online Contributor
To whom does this experiment offer the most potential benefit?
"This clinical trial is seeking 764 participants that suffer from alopecia areata. The study has the following age requirements: 18-70 for males and 18-70 for females. Additionally, applicants must meet the following other conditions: Current episode of severe or very severe AA of less than 8 years (participants who have severe or verysevere AA for ≥8 years may be enrolled if episodes of regrowth, spontaneous or under treatment, have been observed on the affected areas over the past 8 years), current AA episode of more than 6 months' duration and hair loss encompassing ≥50% of the scalp, as measured" - Anonymous Online Contributor
Are elderly patients welcome in this clinical trial?
"All individuals above the age of 18 and under 70 are eligible to participate in this trial." - Anonymous Online Contributor
Is this study also being conducted in other countries besides the United States?
"Multiple locations across the United States are participating in this clinical trial, including but not limited to Yale University School of Medicine in New Haven, Connecticut and California Dermatology & Clinical Research Institute in Encinitas, Kentucky." - Anonymous Online Contributor
How many people have been selected to participate in this trial?
"Unfortunately, this particular study is not currently admitting patients. Although, it was last updated on February 2nd, 2022. There are 93 other studies for alopecia areata and 34 for Baricitinib that are actively recruiting individuals right now." - Anonymous Online Contributor